The Analyst Verdict: United Therapeutics In The Eyes Of 8 Experts
Portfolio Pulse from Benzinga Insights
In the last three months, 8 analysts have rated United Therapeutics (NASDAQ:UTHR) with a mix of bullish and bearish perspectives. The average 12-month price target has increased by 11.46% to $356.38. Analysts have adjusted their ratings and price targets based on market conditions and company performance. United Therapeutics has shown strong financial metrics, including a 19.85% revenue growth rate, a 38.9% net margin, and a low debt-to-equity ratio of 0.09.
August 20, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
United Therapeutics has received mixed analyst ratings, with a recent increase in the average 12-month price target to $356.38. The company's strong financial performance, including a 19.85% revenue growth rate and a 38.9% net margin, supports a positive outlook.
The increase in the average price target and strong financial metrics such as revenue growth and net margin suggest a positive short-term impact on UTHR's stock price. The mixed analyst ratings indicate some uncertainty, but the overall financial health of the company supports a likely upward trend.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100